Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: EC:2.7.11.1 (protein kinase)
81,284 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

To address controversies concerning the effect of beta-adrenergic stimulation on the rate of cross-bridge cycling in cardiac muscle, we measured ca(2+)-induced isometric tension development, unloaded shortening velocity (Vmax) and ATPase activity of demembranated (Triton X-100 skinned) rat right ventricular trabeculae before and after treatment with the catalytic subunit of protein kinase A (PKA), which is known to mimic the action of beta-adrenergic agonists in demembranated preparations. PKA treatment (1 U/microliter, 40 min) shifted the pCa-tension relation to the right from 5.41 to 5.26 at pCa50 (the [Ca2+] required for half maximal steady state tension) without changing the steepness of the pCa-tension relation and the maximum Ca(2+)-activated tension; Vmax, as determined by the slack test, was increased for a given pCa value, despite the reduced level of isometric tension. PKA treatment also shifted the pCa-ATPase activity to the right slightly from 5.47 to 5.40 at pCa50 (the [Ca2+] required for half maximal ATPase activity), but increased the ATPase activity during a given level of steady isometric tension generation, resulting in a 33% increase of the tension cost (ATPase activity/tension). All the results obtained strongly suggest that, in rat right ventricular trabeculae, beta-adrenergic stimulation may increase the rate of cross-bridge cycling by increasing the rate of cross-bridge detachment from actin through a PKA-mediated mechanism, although PKA reduces the Ca(2+)-sensitivity of the contractile system.
J Mol Cell Cardiol 1997 Jun
PMID:Protein kinase A increases the tension cost and unloaded shortening velocity in skinned rat cardiac muscle. 922 Mar 51

The metabolic effects of insulin are initiated by the binding of insulin to the extracellular domain of the insulin receptor within the plasma membrane of muscle and adipose and liver cells. The subsequent activation of the intracellular tyrosine protein kinase activity of the receptor leads to autophosphorylation of the receptor as well as phosphorylation of a number of intracellular proteins. This gives rise to the activation of Ras and phosphatidylinositol 3-kinase and hence to the activation of a number of serine/threanine protein kinases. Many of these kinases appear to be arranged in cascades, including a cascade that results in the activation of mitogen-activated protein kinase and another that may result in the activation of protein kinase B, leading to the inhibition of glycogen synthase kinase-3 and the activation of the 70 kiloDalton ribosomal S6 protein kinase (p70 S6 kinase). We have explored the role of these early events in the the stimulation of glycogen, fatty acid, and protein synthesis by insulin in rat epididymal fat cells. Comparisons have been made between the metabolic effects of insulin and those of epidermal growth factor, since these 2 agents have contrasting effects on p70 S6 kinase and mitogen-activated protein kinase. The effects of wortmannin (which inhibits phosphatidylinositol 3-kinase), and rapamycin (which blocks the activation of p70 S6 kinase) have also been studied. These and other studies indicate that the mitogen-activated protein kinase cascade is probably not important in the acute metabolic effects of insulin, but may have a role in the regulation of gene transcription and hence the more long-term effects of insulin. The short-term metabolic effects of insulin appear to involve at least 3 distinct signaling pathways: (1) those leading to increases in glucose transport and the activation of glycogen synthase, acetyl-CoA carboxylase, eukaryotic initiation factor-2B, and phosphodiesterase, which may involve phosphatidylinositol 3-kinase and protein kinase B; (2) those leading to some of the effects of insulin on protein synthesis (formation of eukaryotic initiation factor-4F complex, S6 phosphorylation, and activation of eukaryotic elongation factor-2), which may involve phosphatidylinositol 3-kinase and p70 S6 kinase; and finally, (3) that leading to the activation of pyruvate dehydrogenase, which is unique in apparently not requiring activation of phosphatidylinositol 3-kinase.
Am J Cardiol 1997 Aug 04
PMID:Multiple signaling pathways involved in the metabolic effects of insulin. 929 55

In patients with congestive heart failure, plasma atrial natriuretic peptide (ANP) and brain natriuretic peptide (BNP) levels are frequently increased, but whether natriuretic peptides act directly on the heart has not been clarified. We investigated the effects of natriuretic peptides on nitric oxide (NO) synthase activity in cardiac myocytes. We measured the production of nitrite, a stable metabolite of nitric oxide, and the expression of inducible NO synthase (iNOS) mRNA and protein in cultured neonatal rat cardiac myocytes. Incubation of cardiac myocytes for 24 h with interleukin-1beta (IL-1beta) caused a significant increase in NO production. ANP, BNP and 8-bromo-cGMP, but not C-type natriuretic peptide (CNP), augmented NO synthesis in IL-1beta-stimulated cardiac myocytes in dose- and time-dependent manners. The same effects of ANP and BNP were observed at different doses of IL-1beta. Simultaneous incubation with IL-1beta in the presence of the NOS inhibitor NG-monomethyl-l-arginine or the RNA synthesis inhibitor actinomycin D for 24 h completely inhibited ANP- and BNP- as well as IL-1beta-induced nitrite production. ANP- BNP-induced NO synthesis in IL-1beta-stimulated cells were accompanied by increased iNOS mRNA and protein levels. The cGMP-dependent protein kinase inhibitor Rp-8-Br-cGMPS completely inhibited the effects of ANP and BNP. These findings indicate that both ANP and BNP up-regulate IL-1beta-induced iNOS expression in cardiac myocytes, which is at least partially mediated via activation of cGMP-dependent protein kinase.
J Mol Cell Cardiol 1997 Sep
PMID:Natriuretic peptides modulate nitric oxide synthesis in cytokine-stimulated cardiac myocytes. 929 61

Adrenoceptor agonists play an important role in cardiac hypertrophy. In cardiomyocytes, activation of alpha- and beta-adrenoceptors induces a variety of hypertrophic responses via activation of protein kinase C (PKC) and protein kinase A (PKA), respectively. Although PKC evokes activation of the Raf-1 kinase (Raf-1)/mitogen-activated protein (MAP) kinase cascade, PKA has been shown to inhibit the activation of Raf-1 and MAP kinases induced by growth factors in various cell types. The present study was performed to elucidate the role of PKA and PKC in cardiomyocyte hypertrophy. PKA activators such as forskolin (FSK), isobutylmethylxanthine, dibutyryl cAMP and isoproterenol, significantly activated Raf-1 and MAP kinases with a peak at 2 and 8 min, respectively, followed by an increase in protein synthesis in cardiac myocytes. Similar responses were observed when cardiomyocytes were stimulated with PKC activators such as 12-O-tetradecanoylphorbol-13-acetate (TPA), angiotensin II, phenylephrine and mechanical stretch. After depleting extracellular Ca2+ with EGTA, FSK did not activate MAP kinases, while down-regulation of PKC by long exposure with TPA did not influence FSK-induced MAP kinase activation. Furthermore, FSK and TPA synergistically activated Raf-1. Similar synergistic activation of MAP kinases was observed when other PKC activators were added to cardiac myocytes with FSK at the same time. In conclusion, unlike other cell types, PKA activates Raf-1 and MAP kinases followed by an increase in protein synthesis in cardiac myocytes.
J Mol Cell Cardiol 1997 Sep
PMID:Protein kinase A and protein kinase C synergistically activate the Raf-1 kinase/mitogen-activated protein kinase cascade in neonatal rat cardiomyocytes. 929 72

We investigated whether parathyroid hormone-related peptide (PTH-rP), recently found expressed in the heart, exerts growth and contractile effects on adult cardiomyocytes from rat hearts. Synthetic PTH-rP peptides were used covering either a protein kinase C (PKC)-activating domain [PTH-rP(107-111)], or an adenylate cyclase activating domain [PTH-rP(1-34) and PTH-rP(7-34)]. PTH-rP(107-111) (1 micro M) increased creatine kinase BB activity (CK-BB), a CK isoform re-expressed during cardiac hypertrophy, within 24 h by 62+/-12%. This induction was abolished in the presence of the mitogen-activated-protein (MAP)-kinase-kinase inhibitor PD 98059. PTH-rP(107-111) activated p42-MAP-kinase within 15 min, increased protein synthesis (19+/- 4%), total protein mass (19+/-5%), cell volume (45+/-7%), and cross-sectional area (38+/-9%) of cardiomyocytes. Activation of p42-MAP-kinase and increase in protein synthesis were abolished in presence of bisindolylmaleimide, a PKC inhibitor. PTH- rP(107-111) did not directly influence contractile activity but reduced the contractile response to isoprenaline. In contrast, PTH-rP(1-34) and PTH-rP(7-34) induced spontaneous contractile activity in 3-day-old cultures. This induction was abolished in presence of Rp-cAMPS, a protein kinase A inhibitor, indicating an involvement of cAMP in this response. PTH-rP(1-34) also increased the cellular accumulation of cAMP. It is concluded that PTH-rP exert direct effects on adult cardiomyocytes by activating either PKC via a functional domain covered by amino acids 107-111 or by activation of cAMP-dependent protein kinase via a functional domain covered by amino acids 7-34. Since these parts of PTH-rP have either no homology [PTH-rP(107-111)] or only a limited structural similarity [PTH-rP(7-34)] to parathyroid hormone, these activities of PTH-rP have to be clearly distinguished from those described for parathyroid hormone.
J Mol Cell Cardiol 1997 Nov
PMID:Effects of PTH-rP(107-111) and PTH-rP(7-34) on adult cardiomyocytes. 940 80

We showed before that partial inhibition of Na/K-ATPase by non-toxic concentrations of ouabain caused hypertrophic growth of neonatal rat cardiac myocytes, and induced several early- and late-response genes that are markers of cardiac hypertrophy. The aim of this study was to determine if the genes of the alpha-subunit isoforms of Na/K-ATPase were among those regulated by ouabain; and if so, to begin the characterization of the pathways regulating these genes. When neonatal myocytes, expressing alpha1- and alpha3-isoform messages, were exposed to 5-100 micro M ouabain, alpha1 mRNA was not affected, but alpha3 mRNA was decreased in a dose- and time-dependent manner. Ouabain-induced down-regulation of alpha3 mRNA was accompanied by a decrease in alpha3-protein content in these myocytes. There was a significant correlation between ouabain effects on alpha3-repression and skeletal alpha-actin induction; also, ouabain's transcriptional effects on both genes were antagonised by retinoic acid. These findings suggested the association of alpha3 repression with ouabain-induced hypertrophy. Phenylephrine and a phorbol ester, two hypertrophic stimuli that do not inhibit Na/K-ATPase, also down-regulated alpha3 mRNA without affecting alpha1 mRNA, suggesting that alpha3-repression is a common feature of the hypertrophic phenotype in these myocytes. Ouabain-induced repression of alpha3 required the influx of extracellular Ca2+, and was antagonized by inhibitors of protein kinase C, Ca2+-calmodulin kinase, and mitogen-activated protein kinase but not by inhibition of protein kinase A. These data, and prior findings on the mechanisms of hypertrophic effects of phenylephrine and phorbol esters, suggest that transcriptional repression of alpha3 by ouabain and other hypertrophic stimuli involves a common step regulated by a mitogen-activated protein kinase.
J Mol Cell Cardiol 1997 Nov
PMID:Differential regulation of Na/K-ATPase alpha-subunit isoform gene expressions in cardiac myocytes by ouabain and other hypertrophic stimuli. 940 89

In recent years, much progress has been made in elucidating the complex but orchestrated series of molecular events that drives a vascular smooth muscle cell to undergo proliferation. These events are initiated by mitogenic stimuli, such as platelet-derived growth factor binding to its receptor and triggering an intracellular signal transduction cascade, leading ultimately to cell-cycle progression and cell division. The signaling pathways that take place in response to both hyperplastic and hypertrophic agents, which include the mitogen-activated protein kinase and p70 S6 kinase, are discussed. In addition, novel protein kinase mediators, such as phosphatidylinositol 3-kinase and protein kinase B, and mechanisms that have recently been implicated in vascular smooth muscle cell growth are described.
Curr Opin Cardiol 1997 Nov
PMID:Molecular mechanisms of vascular smooth muscle cell growth. 942 19

We tested the hypothesis that altered phosphorylation of myofibrillar proteins is involved in post-ischemic myocardial stunning. Myofibrillar proteins were isolated from Langendorff perfused control rabbit hearts, hearts submitted to 15 min normothermic ischemia and hearts submitted to 15 min ischemia followed by 10 min of reperfusion (stunned hearts). The in vivo level of phosphorylation of specific contractile proteins by protein kinases A and C was indirectly detected by the amount of 32P incorporated in vitro in the presence of these protein kinases and saturating concentration of [gamma-32P]-ATP (back-phosphorylation method). In control experiments the back-phosphorylation technique was able to detect PKA- or PKC-induced protein phosphorylation in hearts treated with isoproterenol and phorbol ester, respectively. In stunned hearts, contractile function was significantly suppressed compared to the period before ischemia. We found no difference in myofibrillar protein profile (on densitometry of the Coomassie-stained gels after SDS-PAGE) and in PKA mediated 32P incorporation when comparing control, ischemic and stunned myocardium. Three different PKCs were used for phosphorylation: commercial purified rat brain PKC, partially purified rat brain PKC or rabbit partially purified cardiac PKC. Cardiac PKC mainly phosphorylated troponin I, whereas brain PKC phosphorylated both troponin T and troponin I. No significant difference in 32P incorporation mediated by either brain or cardiac PKC was found between control, ischemic and ischemic/reperfused myofibrils. These data indicate that myocardial stunning does not cause changes in PKC- or PKA-mediated Pi incorporation into myofibrillar proteins detectable by the back-phosphorylation method.
J Mol Cell Cardiol 1997 Dec
PMID:Phosphorylation by protein kinases A and C of myofibrillar proteins in rabbit stunned and non-stunned myocardium. 944 26

Effects of acetylcholine (ACh) on the L-type calcium current were examined in isolated atrioventricular nodal cells that exhibited spontaneous contractions. ACh (0.1 to 10 microM) inhibited basal calcium current dose-dependently. This inhibition was eliminated by dialysis with 8Br cAMP or cAMP-dependent kinase inhibitory peptide. Both extracellular N-ethylmaleimide 50 microM and intracellular GDPssS 0.2 mM abolished the ACh effect. Dialysis with cGMP or NG-monomethyl-L-arginine did not significantly affect ACh inhibition of basal calcium current. Similarly, cGMP-dependent protein kinase inhibitor KT5823 (1 microM) and the type II phosphodiesterase inhibitor erythro-9-(2-hydroxy-3-nonyl) adenine (30 microM) did not attenuate the ACh effect. Therefore, ACh inhibits the basal calcium current in the atrioventricular node mainly by suppressing cAMP synthesis through the inhibitory GTP-binding protein.
Can J Cardiol 1997 Dec
PMID:Muscarinic inhibition of basal L-type calcium current in pacemaker cells from the rabbit atrioventricular node. 944 1

We have previously established that the secosteroid hormone 1alpha, 25-dihydroxy-vitamin D3 [1,25(OH)2D 3] rapidly stimulates dihydropyridine-sensitive calcium channel-mediated Ca2+ influx in chick cardiac muscle by a non-genomic action which is accompanied by phosphorylation of microsomal proteins. In the present study, we investigated the participation of the cyclic AMP/protein kinase A (PKA) signalling pathway in hormone-induced changes on protein phosphorylation in chick heart tissue. A major increase in the phosphorylation of a microsomal protein of 45 kDa, and, to a lesser extent, of a protein of 70 kDa, was observed after incubation with [gamma-32P]ATP of membranes isolated from heart thin slices (HTS) pretreated for 1-5 min with 1,25(OH)2D3. This effect was dose- and time-dependent, reaching a maximum after 3 min and at the physiological concentrations of 10(-10) and 10(-11) M. 1,25(OH)2D3 steadily increased cellular cAMP levels as a function of the dose (10( -12)-10(-9) M). The specific agonist of PKA, Sp-cAMPS and the PKA catalytic subunit stimulated the phosphorylation of the same membrane proteins as the hormone. The 1alpha,25-dihydroxy-vitamin D3-dependent changes in microsomal protein phosphorylation were diminished by the specific PKA inhibitor, Rp-cAMPS. In addition, the PKA activity ratio (-cAMP/+cAMP) increased 60% above the control after treatment of HTS with 10(-11) M 1,25(OH)2D3. The data obtained clearly indicate that activation of the cAMP/PKA signalling pathway mediates the stimulation of protein phosphorylation by 1alpha, 25-dihydroxy-vitamin D3 in chick cardiac muscle.
J Mol Cell Cardiol 1998 Feb
PMID:Studies suggesting the participation of protein kinase A in 1, 25(OH)2-vitamin D3-dependent protein phosphorylation in cardiac muscle. 951 99


<< Previous 1 2 3 4 5 6 7 8 9 10 Next >>